Medical Director - Molecular Oncology & Genomics

The Medical Director for Oncology & Genomics is a senior position for a physician with both laboratory and clinical experience who will serve as an expert on the clinical use of testing in solid and liquid cancer as well as the understanding the hematologic aspects of the testing space. The ideal candidate should have experience with clinical management of patients with cancer and understand the hematologist/ oncologist's needs, experience and expectations concerning the use of heme and cancer-related diagnostics.

The Medical Director will have responsibility for leading clinical research efforts directed towards developing projects that assess the clinical utility of our oncologic testing platforms and establishing the scientific credibility of our test offerings to outside stakeholders in support of our commercial efforts. To achieve this mission, the Oncology Director role requires an appreciation of current and future clinical trends, standards of care, critical trials being carried out by others and third-party reimbursement issues. The Director will pursue impactful collaborations and publications in close coordination with Medical Scientific Affairs, the Oncology Product team and Market Access departments. The director will share his/her clinical knowledge and experience with the Development team in order to advise the team on current product revisions and future product development.

The role will be supported by the Chief Medical Officer.

The Medical Director will serve as the primary consultant in oncology internally to the commercial and marketing teams and externally to physicians, professional societies, health insurers, and patients. Activities will include scientific educational presentations at conferences and other venues and communication with clients on Quest Diagnostic's Oncology test offerings in the oncology space. The individual must be able to have productive peer-to-peer relationships as an honest, credible partner in healthcare, nurturing positive relationships with oncology KOLs and practicing clinicians.